Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 6/20 | 0.40 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | SMYD3 | Q9H7B4 | 3/20 | 0.37 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.37 |
| ▸ | HTR3B | O95264 | 3/20 | 0.37 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.37 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8939948 | 0.89 | HTR3A (0.44) | HTR3AHTR4MEN1KMT2ASMYD3 | |
| SCHEMBL8939963 | 0.86 | HTR3A (0.45) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL8939990 | 0.83 | MEN1 (0.43) | HTR3AHTR4MEN1KMT2AHTR3E | |
| SCHEMBL8940096 | 0.83 | MEN1 (0.46) | HTR3AHTR4MEN1KMT2AHTR3E | |
| SCHEMBL8940123 | 0.82 | HTR4 (0.48) | HTR3AHTR4MEN1KMT2A | |
| Zatosetron SCHEMBL30949358 | 0.82 | HTR3A (0.51) | HTR3AHTR4MEN1KMT2A | |
| Zatosetron SCHEMBL466400 | 0.82 | HTR3A (0.51) | HTR3AHTR4MEN1KMT2A | |
| Zatosetron SCHEMBL466399 | 0.82 | HTR3A (0.51) | HTR3AHTR4MEN1KMT2A | |
| Zatosetron SCHEMBL466401 | 0.82 | HTR3A (0.51) | HTR3AHTR4MEN1KMT2A | |
| SCHEMBL8939935 | 0.82 | HTR3A (0.46) | HTR3AHTR4MEN1KMT2AHTR3E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5563148-A | BICYCLIC ESTERS OR AMIDES; USED IN TREATING MIGRAINE, EMESIS, GASTROINTESTINAL DISORDERS, SCHIZOPHRENIA OR ANXIETY IN MAMMALS | ELI LILLY AND COMPANY (US) | 1996-10-08 | — | — | US | disclosed |
| EP-0307172-B1 | Improvements in or relating to specific 5-HT3 antagonists | LILLY CO ELI (US) | 1995-10-11 | — | — | EP | disclosed |
| US-5442078-A | Intermediates for specific 5-HT3 antagonists | ELI LILLY AND COMPANY (US) | 1995-08-15 | — | — | US | disclosed |
| US-5364863-A | Treatment of migraine, emesis, schizophrenia, anxiety, gastrointestinal disorders | ELI LILLY AND COMPANY (US) | 1994-11-15 | — | — | US | disclosed |
| US-4997956-A | Analgesics | ELI LILLY AND COMPANY (US) | 1991-03-05 | — | — | US | disclosed |
| US-4921982-A | 5-halo-2,3-dihydro-2,2-dimethylbenzofuran-7-carboxylic acids useful as intermediates for 5-HT3 antagonists | ELI LILLY AND COMPANY (US) | 1990-05-01 | — | — | US | disclosed |
| EP-0307172-A2 | Improvements in or relating to specific 5-HT3 antagonists | ELI LILLY AND COMPANY (US) | 1989-03-15 | — | — | EP | disclosed |